Lupin Eyes 20% Growth Rate In U.S. From 110 Applications To FDA
This article was originally published in PharmAsia News
Executive Summary
Lupin is aiming for a 20% growth rate in the U.S. market, relying on approvals of many of the 110 drugs it has filed for approval by the FDA within the next four years, according to S Ramesh, President and CFO.